Compare CLDX & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLDX | GRDN |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Retail-Drug Stores and Proprietary Stores |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2008 | 2024 |
| Metric | CLDX | GRDN |
|---|---|---|
| Price | $23.83 | $33.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $41.56 | $33.33 |
| AVG Volume (30 Days) | ★ 666.2K | 271.1K |
| Earning Date | 02-26-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.28 |
| Revenue | $2,599,000.00 | ★ $1,389,638,000.00 |
| Revenue This Year | N/A | $19.50 |
| Revenue Next Year | $23.23 | N/A |
| P/E Ratio | ★ N/A | $121.54 |
| Revenue Growth | N/A | ★ 18.68 |
| 52 Week Low | $14.40 | $17.78 |
| 52 Week High | $30.50 | $37.43 |
| Indicator | CLDX | GRDN |
|---|---|---|
| Relative Strength Index (RSI) | 35.84 | 62.23 |
| Support Level | $22.55 | $30.85 |
| Resistance Level | $25.60 | $33.00 |
| Average True Range (ATR) | 1.05 | 1.43 |
| MACD | -0.30 | 0.32 |
| Stochastic Oscillator | 8.05 | 98.07 |
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.